Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2251 publications
Evaluating Efficacy Outcomes in Pediatric Multiple Sclerosis Patients While Using Avonex or Plegridy via USNPMSC Registry.
Journal: Journal of child neurology
Published: September 16, 2025
Matching-adjusted indirect comparisons of diroximel fumarate, ocrelizumab and interferon beta-1a for relapsing multiple sclerosis.
Journal: Journal of comparative effectiveness research
Published: September 12, 2025
Outcomes of older patients with multiple sclerosis treated with interferon beta-1a or peginterferon beta-1a in MS PATHS.
Journal: Neurodegenerative disease management
Published: July 15, 2025
Therapeutic evaluation of immunomodulators and immunosuppressants in progressive multiple sclerosis: summary of a Cochrane systematic review.
Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Published: June 15, 2025
A multicentre, prospective, randomized, open-label pragmatic trial to compare the effectiveness and safety of interferon beta-1a and glatiramer-acetate in paediatric patients affected by Multiple Sclerosis.
Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Published: June 11, 2025
What Is the Evidence on Immunomodulators and Immunosuppressants for Progressive Multiple Sclerosis? - A Cochrane Review Summary with Commentary.
Journal: NeuroRehabilitation
Published: June 09, 2025
Expression profiling of Wnt/β-catenin, antimicrobial peptides, endoplasmic reticulum stress, and apoptosis signaling pathways and antioxidant/oxidant status in Oreochromis niloticus following Proteus mirabilis challenge: the palliative role of naringenin flavanone.
Journal: Fish & shellfish immunology
Published: May 28, 2025
Performance of Composite Endpoints Defining Progression Independent of Relapse Activity in Multiple Sclerosis.
Journal: Annals of clinical and translational neurology
Published: May 23, 2025
A disproportionality analysis of nervous system adverse events associated with disease-modifying therapies in multiple sclerosis: insights from the FDA adverse event reporting system (FAERS).
Journal: Journal of neurology
Published: April 16, 2025
Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: April 16, 2025
Drug-Related epileptic seizures and Age-Specific Differences: A Real-World study based on the FAERS database.
Journal: Epilepsy & behavior : E&B
Published: April 12, 2025
Characterization of Proteomic Pharmacodynamic Biomarkers of IFNβ-1a Biologics to Inform Potential Utility in Biosimilar Development.
Journal: Clinical pharmacology and therapeutics
Published: March 28, 2025
Last Updated: 10/31/2025